This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Polakowski, I. J. Articles by Auerbach, R. Search for Related Content PubMed PubMed Citation Articles by Polakowski, I. J. Articles by Auerbach, R.

American Journal of Pathology, Vol 143, 507-517, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice

IJ Polakowski, MK Lewis, VR Muthukkaruppan, B Erdman, L Kubai and R Auerbach
Center for Developmental Biology, University of Wisconsin, Madison 53706.

Our experiments were designed to determine whether recombinant ribonuclease inhibitor (RNasin) could inhibit angiogenesis and reduce tumor growth in adult mice. We used the Fajardo disc angiogenesis assay as the primary means of measuring new blood vessel growth. This assay measures the penetration of cells into a polyvinyl alcohol sponge with a central core of ELVAX-coated sponge containing test substances. Cell penetration was reduced to 29.3% of control (phosphate-buffered saline; heat-inactivated RNasin) values. Endothelial cell influx was measured by lectin staining and confirmed by culturing cells isolated from sponges by collagenase treatment. RNasin also reduced the augmented reaction evoked by either basic fibroblast growth factor (bFGF) or sodium orthovanadate. To confirm the anti-angiogenic activity of RNasin, Hydron-coated polyvinyl sponges containing bFGF or bFGF plus RNasin were implanted into adult mouse corneas. bFGF induced a strong angiogenic response that was almost completely inhibited by RNasin. RNasin-containing ELVAX-coated sponges implanted subcutaneously underneath an intradermal inoculum of C755 mammary tumor cells caused significant reduction in tumor growth (P < 0.005). The antitumor effect of RNasin correlated with its effect on tumor-induced neovascularization, suggesting that the ability of RNasin to affect tumor growth was due to its ability to inhibit angiogenesis.

This article has been cited by other articles:

				K. Kumar, M. Brady, and R. Shapiro Selective abolition of pancreatic RNase binding to its inhibitor protein PNAS, January 6, 2004; 101(1): 53 - 58. [Abstract] [Full Text] [PDF]

				Y. Hamma-Kourbali, R. Vassy, A. Starzec, V. Le Meuth-Metzinger, O. Oudar, R. Bagheri-Yarmand, G. Perret, and M. Crepin Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165{middle dot}KDR Complexes J. Biol. Chem., October 19, 2001; 276(43): 39748 - 39754. [Abstract] [Full Text] [PDF]

				K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]

				R. T. Raines, M. P. Toscano, D. M. Nierengarten, J. H. Ha, and R. Auerbach Replacing a Surface Loop Endows Ribonuclease A with Angiogenic Activity J. Biol. Chem., July 21, 1995; 270(29): 17180 - 17184. [Abstract] [Full Text] [PDF]

				S. Gengrinovitch, S. M. Greenberg, T. Cohen, H. Gitay-Goren, P. Rockwell, T. E. Maione, B.-Z. Levi, and G. Neufeld Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF[IMAGE] and VEGF[IMAGE] Using Several Concurrent Mechanisms J. Biol. Chem., June 23, 1995; 270(25): 15059 - 15065. [Abstract] [Full Text] [PDF]